Table 5.
Drug repurposing predictions made by the best-performing topological link prediction model (RotatE). Also shown are current approved indications and (if available) clinical trials investigating the efficacy of the drug for treating Alzheimer disease (AD).
| Drug name | Approved indications | AD-related clinical trials |
| Sumatriptan | Migraines and cluster headaches | —a |
| Nicotine | Nicotine withdrawal symptoms | NCT00018278 (completed) |
| Pimozide | Tourette disorder | — |
| Risperidone | Schizophrenia, bipolar mania, and psychosis | NCT00034762 (completed) |
| Flurbiprofen | Osteoarthritis and rheumatoid arthritis | — |
| Sertraline | Depressive disorder and social anxiety disorder | NCT00086138 (completed); NCT00009191 (completed) |
| Clozapine | Schizophrenia | — |
| Tamoxifen | ER+b breast cancer | — |
| Amiodarone | Recurrent hemodynamically unstable ventricular tachycardia and recurrent ventricular fibrillation | — |
| Chlorpromazine | Nausea, vomiting, preoperative anxiety, schizophrenia, bipolar disorder, and severe behavioral problems in children | — |
aNo known AD-related clinical trials for the given drug.
bER+: estrogen-receptor positive.